基于三级氨基氧化物zwitterionic聚合物用于动脉样硬化治疗的ROS响应的simvastatin纳米前药物
Haiqin Yang1, Mengcheng Guo1, Qingran Guan1
1Key Laboratory of Special Engineering Plastics Ministry of Education, College of Chemistry, Jilin University, Changchun, Jilin, 130012, China.
Journal of nanobiotechnology
|March 6, 2025
概括
一种新型纳米前药物OPDH-SV有效降低了动脉样硬化中的氧化应激和脂质水平. 这种基于simvastatin的疗法在治疗心血管疾病方面具有很好的生物安全性和治疗效果.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 心血管研究研究心血管研究
背景情况:
- 动脉样硬化 (AS) 是导致心血管疾病的主要原因,其特征是活性氧物种 (ROS) 和脂质积累的增加.
- 目前的治疗方法在向的治疗和管理疾病进展方面面临挑战.
研究的目的:
- 设计和评估一种ROS响应的simvastatin纳米原药 (OPDH-SV) 用于动脉样硬化治疗.
- 评估OPDH-SV的体外和体内疗效,稳定性和生物安全性.
主要方法:
- 通过ROS响应的氧酸盐键,将simvastatin (SV) 与三级氨基氧化物zwitterionic聚合物 (OPDH) 结合.
- 在体外研究:稳定性,毒性,ROS/脂质减少和泡细胞抑制的评估.
- 在体内研究:血液循环时间的评估,向丰富和ROS/脂质水平的降低.
主要成果:
- OPDH-SV在体外表现出极好的稳定性和低毒性.
- 这种纳米原药有效地降低了细胞内ROS和脂质水平,抑制了泡细胞的形成.
- OPDH-SV通过内细胞体外流和向线粒体表现出细胞对细胞的传播.
- 在体内研究证实了长期循环,有针对性的丰富,并显著降低ROS和脂质水平.
结论:
- OPDH-SV表现出有利的生物安全性和强大的体内治疗作用,对动脉样硬化.
- 这种对ROS敏感的纳米前药物具有作为抗动脉样硬化治疗的新疗法战略的潜力.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
501
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
501
Antihypertensive Drugs: Vasodilators
455
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
455
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
433
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
433
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
695
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
695
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
440
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
440
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
749
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
749


